Table 4 Clinicopathological characteristics of the patients with and without irAEs
|  | irAEs + (n = 15) | irAEs − (n = 63) | P value |
|---|---|---|---|
Age | 65 (41–81) | 67 (38–88) | 0.560 |
Sex | Â | Â | 0.116 |
 Male | 9 (60.0) | 50 (79.4) |  |
 Female | 6 (40.0) | 13 (20.6) |  |
ECOG PS | Â | Â | 0.701 |
 0/1 | 13 (86.7) | 52 (82.5) |  |
 2/3 | 2 (13.3) | 11 (17.5) |  |
Disease status | Â | Â | 0.947 |
 Unresectable | 8 (53.3) | 33 (52.4) |  |
 Recurrence | 7 (46.7) | 30 (47.6) |  |
Histology | Â | Â | 0.142 |
 Differentiated | 12 (80.0) | 33 (52.4) |  |
 Undifferentiated | 3 (20.0) | 28 (44.4) |  |
 Unknown | 0 | 2 (3.2) |  |
HER2 status | Â | Â | 0.108 |
 Positive | 6 (40.0) | 11 (17.5) |  |
 Negative | 8 (53.3) | 38 (60.3) |  |
 Unknown | 1 (6.7) | 14 (22.2) |  |
Number of previous treatments | Â | Â | 0.700 |
 2 | 13 (86.7) | 52 (82.5) |  |
 3 / 4 | 2 (13.3) | 11 (17.5) |  |
Response to nivolumab treatment |  |  |  < 0.001 |
 CR/PR/SD | 13 (86.7) | 27 (42.9) |  |
 PD | 2 (13.3) | 36 (57.1) |  |